An interventional study of Nu.T and No-Treatment Control in Intermittent Exotropia, sponsored by Nunaps Inc. Completed at 6 sites in South Korea. Open to participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Nunaps Inc · Not applicable, Interventional, and Treatment
This study evaluates the efficacy and safety of visual perceptual learning for improving stereopsis in intermittent exotropia. Half of participants will receive visual perceptual training using the Nu.T. The other half will not receive any training because there is no standard treatment for decreased stereopsis in intermittent exotropia.
58 studies on the registry are indexed under Exotropia; 13 are open to participants now.
This study's enrollment of 54 is close to the median of 50 across 49 interventional studies indexed under Exotropia.
Browse Exotropia studies →Nunaps Inc is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nu.T, 5 times a week for 8 weeks.
Device: Nu.T
No-treatment was administered during control period.
Other: No-Treatment Control
Participants receive visual perceptual training using the Nu.T software.
No-treatment was administered during control period.
Changes in (log) arc second of stereopsis from Baseline to 8 weeks
Stereopsis will be evaluated by a Titmus Dot Test.
Time frame: 8 weeks
Proportion of subjects showing improved stereopsis at 8 weeks compared to baseline
Improved stereopsis means more than 2 steps increase in Titmus Dot Test.
Time frame: 8 weeks
Changes of Stereopsis based on Titmus Symbol Test from baseline to 8 weeks
Stereopsis will be evaluated by Titmus Symbol Test.
Time frame: 8 weeks
Changes of Stereopsis based on Distance Randot Stereotest from baseline to 8 weeks
Stereopsis will be evaluated by Distance Randot Stereotest.
Time frame: 8 weeks
Changes of strabismus angle from baseline to 8 weeks
Strabismus angle will be evaluated by distance and near-field.
Time frame: 8 weeks
Changes of convergence capability score from baseline to 8 weeks
Convergence capability will be evaluated in distance and near-field by LACTOSE System. The scores by LACTOSE System range from 0 to 4.
Time frame: 8 weeks
Changes of visuo-motor function from baseline to 8 weeks.
Visuo-motor function will be evaluated by the Bruininks-Oseretsky Test of Motor Proficiency Second Edition (BOT-2) test.
Time frame: 8 weeks
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nunaps Inc